Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

NCT03377491 is registered in ClinicalTrials.gov with NovoCure Ltd. as lead sponsor.

NCT NCT03377491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03377491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Lead sponsor
NovoCure Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2018
Completion date
October 16, 2024
Enrollment
571 (actual)
Sites
199

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas adenocarcinoma